FDA Approves Zegerid OTC for Over-the-counter Treatment of Frequent Heartburn

printsend

Merck has announced that the FDA has approved Zegerid OTC (omeprazole 20 mg/sodium bicarbonate 1,100 mg capsules), for over-the-counter treatment of frequent heartburn.

Zegerid OTC is a proton pump inhibitor, the strongest and most effective class of acid-reducing medications available for frequent heartburn. The medication treats frequent heartburn by controlling and suppressing acid for a full 24 hours. It contains a dual-ingredient formulation that combines the leading prescription acid reducing medicine, omeprazole, with sodium bicarbonate, which protects the omeprazole from acid in the stomach. Zegerid OTC capsules will be available in their original prescription formula and are expected to be available in the first half of 2010.

The approval provides a new and unique over-the-counter option for the estimated 50 million adults in the U.S. who experience symptoms associated with frequent heartburn, which is defined by symptoms occurring more than two times per week. Up to 25 million adults in the U.S. experience heartburn daily.

Zegerid OTC is a 14-day course of treatment taken once a day to treat frequent heartburn as directed. More information about the medication is available at www.ZegeridOTC.com.

Santarus, a specialty pharmaceutical company, will continue to manufacture, promote and sell prescription Zegerid (omeprazole/sodium bicarbonate) products in both 20 mg and 40 mg dosage strengths in the U.S.

Contact:
Julie Lux
908-298-4774